Xenios AG

is a commercial-stage company and the recognized technology leader in minimally invasive medical devices that unite one console (XENIOS) with next-generation lung and heart therapies into a single platform for a market with revenue potential of nearly $9 billion.

Lung Failure

XENIOS is the first to offer a complete product family of state-of-the-art solutions for minimally invasive treatment of acute and chronic lung failure without mechanical ventilation and without the need for patient sedation and mobilization.

Heart Failure

XENIOS is the first to offer synchronized cardiac assist, which provides cardiac support in harmony with each heartbeat, designed to unite myocardial protection with organ perfusion.

Latest News

XENiOS AG enrolls first patient in “SynCor” clinical trial of its i-cor device to treat cardiogenic shock